dewpoint logo


June 24, 2024

Dewpoint Therapeutics Welcomes Dr. Lis Leiderman as Chief Financial and Corporate Development Officer

BOSTON, Massachusetts, June 24, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that is translating the novel science of condensates into breakthrough therapeutics, today announced the appointment of Lis Leiderman, M.D., MBA, as Chief Financial and Corporate Development Officer effective today.

Dr. Leiderman is a seasoned biotech leader with 20 years experience at the intersection of medical innovation and healthcare investment banking. She excels in fundraising, capital structure, financial analysis, and valuation. During her dynamic career, she has supported the growth of life science organizations such as Bluebird Bio, Autolus Therapeutics, Atsena Therapeutics where she raised $32M in series B, Decibel Therapeutics for which she led a $125M IPO and $82M series D, Complexa and Fortress Biotech. Her M&A and business development skills include corporate growth strategies, opportunity analysis, due diligence, and transaction leadership.

Ameet Nathwani, CEO of Dewpoint Therapeutics said: “We are excited to welcome Lis Leiderman at a time when Dewpoint is preparing to write the next chapter in its history by bringing its first condensate modifier to the clinics. Along her rich career, Dr. Leiderman has built senior relationships across pharma, biotech, KOLs, bankers, analysts, and investors, earning a strong reputation for integrity and effective team management. I am confident her deep finance, business and medical expertise will be invaluable to our company.”

At Dewpoint, Lis Leiderman will be a strategic partner to the Chief Executive Officer and will work closely with the company leadership and Board of Directors to further build value and shape the company for medium and long-term success. She will have primary responsibility for leading financial and business-related activities including strategic finance, corporate and business development, accounting, treasury, tax, and investor relations.

Media Contact

Investor Contact

Michael Fenn, PH.D.
Head of External Innovation
Dewpoint Therapeutics
dewpoint logo
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science